Form 4: C4 Therapeutics Director Exercises Stock Options

C4 Therapeutics Director Kenneth Carl Anderson exercised stock options for 1,070 shares of common stock on June 1, 2026.

Summary

• Kenneth Carl Anderson, a Director at C4 Therapeutics, Inc., exercised stock options on June 1, 2026.
• The transaction involved 1,070 shares of common stock acquired at an exercise price of $2.11 per share.
• Following the exercise, Anderson directly owns 1,070 shares.
• Additional shares are beneficially owned indirectly through various trusts, including the Kenneth C. Anderson 2021 Irrevocable Trust (129,877 shares), Kenneth C. Anderson 2015 Irrevocable Trust (74,581 shares), Cynthia E. Anderson 2015 Irrevocable Trust (74,581 shares), Kenneth C. Anderson Revocable Trust (3,623 shares), and Cynthia E. Anderson Revocable Trust (3,623 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction without providing company performance data or strategic insights.

Positives

• Director Kenneth Carl Anderson has exercised stock options, indicating potential confidence in the company's future value.
• The exercise of options at $2.11 per share suggests the current market price may be at or above this level.

Negatives

• The filing only details a stock option exercise by a director and does not provide broader company financial performance data, making it difficult to assess overall company health.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, which solely reports a transaction by a director.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions and do not typically contain strategic updates or financial performance metrics. This filing indicates a director's personal investment activity rather than a company-wide announcement.

Stakeholder Impact

• Shareholders: This transaction provides insight into a director's personal holdings and potential confidence, but does not directly impact share price or company operations.

Key Dates

Keywords

C4 Therapeutics, Form 4, Stock Options, Insider Trading, Director Transaction, Beneficial Ownership, Securities Exchange Act